The number of patients with End-State Liver Disease in the United States is expected to continue to grow dramatically in the next ten years. This is largely due to the burden of chronic viral hepatitis which already exists in our population. As these patients age, a larger number will develop decompensation events such as variceal bleeding, hepatic encephalopathy, hepatocellular carcinoma, hyponatremia and renal failure.
Thrombocytopenia (platelet count <150,000/μL) is a common complication in patients with chronic liver disease and has been observed in up to 76% of patients. Thrombocytopenia can impact routine care of patients with CLD, potentially postponing or interfering with diagnostic and therapeutic procedures including liver biopsy, antiviral therapy, and medically indicated or elective surgery.
Currently, many patients undergo platelet transfusions prior to treatment procedure. This adds time, cost and patient discomfort. New therapeutic options to safely and effectively raise platelet levels and the most promising can stimulate Thombroprotein (TPO) production. This significantly reduces the need for platelet transfusions and facilitates the use of antiviral therapy and other medically indicated treatments in patients with liver disease.
This seminar will address:
- The causes and complications of chronic liver disease
- Cirrhosis, Gastroesophageal bleeding and the Liver transplant process
- Promising treatments for Thrombocytopenia in liver disease patients
Those who complete this activity will better understand how to screen, diagnose and effectively treat their patients and be more confident of when and how to refer to Hepatology for more advanced care.
Click here to register today!